01Role and principlesWho benefits and the main preventive aims.
Kidney recovery ranges from rapid return to the previous baseline through partial recovery, recurrent injury, prolonged dialysis dependence and transition to chronic kidney disease. Creatinine may fall because filtration improves, but it can also fall as muscle mass declines after critical illness; fluid balance also changes its concentration. A robust judgement uses serial values, urine output, clinical state and the original baseline. The term ‘resolved AKI’ should therefore be accompanied by evidence and a plan rather than treated as a discharge endpoint.
Follow-up intensity reflects residual risk. Severe stage, prolonged oliguria, renal replacement therapy, incomplete recovery, heart failure, transplant, significant albuminuria, recurrent episodes and an uncertain or intrinsic cause justify earlier testing and specialist input. A stable person with fully recovered mild haemodynamic AKI may need less urgent review, but still needs documentation and medicine reconciliation. NICE deliberately does not impose one universal interval: timing depends on stability and impairment at discharge.
Post-AKI care is also cardiovascular and pharmacological care. Renin–angiotensin system blockers, diuretics and other agents are often interrupted appropriately during shock, hyperkalaemia or volume depletion, yet permanent accidental cessation may worsen heart failure, blood pressure or albuminuric CKD. Conversely, automatic restart before perfusion and potassium stabilise can precipitate recurrence. Shared ownership among the discharging team, general practice, pharmacy and nephrology prevents both errors. These learning notes are not a clinical-approval document; local discharge standards and current disease-specific prescribing guidance govern individual care.
Key points
- Recovery is a trajectory, not a single discharge creatinine: compare with the pre-illness baseline, peak, dialysis requirement, current urine output and subsequent stability.
- NICE advises monitoring creatinine after an AKI episode, with frequency based on how stable renal function is and how impaired it remains at discharge.
- An apparent return to baseline does not erase risk; previous AKI predicts recurrence, later CKD and cardiovascular events, so the episode must remain visible in the record.
- A discharge summary should name AKI stage and cause, baseline and peak values, degree of recovery, unresolved abnormalities, medicine changes and exactly who will review which test and when.
- Reconcile every withheld or dose-reduced medicine. Restart decisions should recover the original prognostic benefit while accounting for current volume status, potassium and kidney function.
- Persistent haematuria, significant albuminuria, systemic features, an unclear cause, dialysis-requiring injury or eGFR 30 mL/min/1.73 m² or below after recovery supports renal discussion or referral.
- Check blood pressure and urine albumin as well as filtration during longer-term review; creatinine recovery can coexist with glomerular damage or newly unmasked CKD.
- Give practical prevention advice: maintain appropriate hydration, avoid non-prescribed NSAIDs, seek help during dehydrating illness, and follow a clear temporary medicine plan with explicit restarting instructions.
02Assessment and patient selectionRisk features, eligibility and important cautions.
Creatinine returns close to a credible pre-illness baseline, urine output and fluid state are stable, and no complication persists. This lowers immediate concern but does not remove future recurrence or CKD risk.
Creatinine falls from its peak yet remains clearly above baseline or eGFR remains reduced. Confirm that the trend is stable after discharge and investigate persistent protein, blood, obstruction or systemic disease rather than assuming slow tubular recovery.
A renewed rise after initial improvement may follow recurrent infection, poor intake, congestion, hypotension, urinary obstruction or a medicine change. Reapply AKI criteria and assess urgently according to the speed and physiological consequences.
Reduced GFR or a marker of kidney damage persisting for at least 90 days establishes chronicity. Earlier abnormal results require follow-up but should not be labelled irreversible before duration and context are known.
Dialysis-requiring AKI, suspected glomerular or interstitial disease, persistent substantial albuminuria or haematuria, transplant, unclear aetiology, recurrent injury or poor recovery warrants renal discussion using the local referral pathway.
Congestion and under-filling can both cause renal dysfunction. Weight, symptoms, blood pressure, diuretic need and prognostic therapy must be reviewed together so fear of creatinine does not leave decompensated heart failure untreated.
03Baseline assessmentMeasurements that guide the plan and track progress.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Serial creatinine, eGFR and electrolytesFirst step - Why
- Confirm stability or continued recovery, detect recurrent injury and support medicine dosing and restart decisions.
- Interpretation and limitations
- Compare baseline, peak, discharge and follow-up values on a dated graph. Frequency is earlier and closer when function is unstable or markedly impaired; interpret eGFR cautiously until creatinine reaches a new steady state.
- 02
Urine albumin-to-creatinine ratio - Why
- Detect residual kidney damage and refine long-term renal and cardiovascular risk after the acute phase.
- Interpretation and limitations
- Measure when acute infection, visible blood and major physiological disturbance no longer confound the result, commonly as part of the approximately three-month kidney review. Confirm persistent elevation and follow the current CKD pathway.
- 03
Urinalysis and urine microscopy when indicated - Why
- Reassess haematuria, protein, leukocytes or casts that suggest an unresolved intrinsic process.
- Interpretation and limitations
- Persistent blood with protein is not a routine footprint to ignore after AKI. Exclude urinary infection and seek nephrology or urology input according to the pattern, symptoms and cancer-risk pathway.
- 04
Blood pressure, weight and congestion assessment - Why
- Identify hypertension, postural hypotension, recurrent depletion or fluid retention that changes kidney and medicine management.
- Interpretation and limitations
- Interpret sitting or standing pressure with symptoms, usual values, jugular venous pressure, oedema, lung findings and weight trend. A creatinine rise during decongestion may need specialist interpretation rather than reflex fluid administration.
- 05
Full medication reconciliation - Why
- Find temporary holds, renal dose changes, interacting nephrotoxins and medicines unintentionally omitted at transfer.
- Interpretation and limitations
- For each medicine document its original indication, current contraindication, restart criterion and monitoring owner. Pay attention to ACE inhibitors, ARBs, mineralocorticoid antagonists, diuretics, diabetes drugs, anticoagulants, antimicrobials and analgesia.
- 06
Renal tract imaging or cause-specific tests - Why
- Confirm resolution when obstruction, structural disease or an unexplained intrinsic process remains possible.
- Interpretation and limitations
- Repeat or complete imaging when drainage status, hydronephrosis or anatomy remains uncertain. Serology, electrophoresis or biopsy decisions belong with nephrology and should follow the original clinical pattern, not a generic post-AKI panel.
04InterventionsLifestyle, treatment and escalation options.
01Before dischargeDefine recovery and hand over riskFirst stepAn inpatient AKI episode is improving sufficiently for discharge or transfer to another care setting.+
- 11. Record the credible baseline, highest stage, likely causes, peak and latest creatinine, urine-output course, complications, imaging, renal replacement therapy and residual abnormalities.
- 22. Reconcile every prescription and state which drugs were stopped, reduced or started, why this occurred, and the clinical and biochemical conditions for review or restart.
- 33. Choose test timing from renal stability, discharge impairment and comorbidity; name the responsible clinician or service and create a result-action plan rather than saying only ‘GP to repeat U&Es’.
- 44. Explain AKI and recurrence warning symptoms to the patient or carer in accessible language, including safe fluid and non-prescribed NSAID advice and how to seek urgent help.
02Early reviewConfirm stability and restore treatmentThe planned first community, hospital or virtual assessment occurs after discharge.+
- 11. Ask about intake, vomiting or diarrhoea, urine volume, breathlessness, swelling, weight change, dizziness, urinary symptoms and use of over-the-counter medicines.
- 22. Check creatinine, potassium and other indicated electrolytes at the planned interval, comparing with discharge and baseline rather than interpreting the eGFR category alone.
- 33. Review volume and blood pressure, then restart or titrate prognostic and symptom-control medicines when their indication remains and current physiology permits, with repeat monitoring booked.
- 4Escalation4. Escalate a renewed rise, severe electrolyte disturbance, congestion, hypotension or unresolved diagnostic warning pattern instead of waiting for the routine three-month assessment.
03Kidney health reviewDetect CKD and reduce recurrent riskThe patient reaches a stable later review, often around three months, or remains abnormal sooner.+
- 11. Establish whether reduced filtration or another damage marker has persisted long enough to diagnose CKD, and stage using both GFR and albuminuria where appropriate.
- 22. Check blood pressure, cardiovascular risk, diabetes control, smoking and exposure to nephrotoxins; optimise treatment under the relevant NICE and UKKA guidance.
- 33. Refer or discuss with nephrology for eGFR 30 or below after recovery, significant albuminuria or haematuria, progressive decline, recurrent AKI, an uncertain intrinsic cause or local high-risk criteria.
- 44. Add the AKI history to ongoing records, agree long-term monitoring frequency and reinforce a precise acute-illness plan that includes when temporarily withheld medicines should restart.
05Medicines and treatment safetyRegimens, contraindications and review points.
ACE inhibitor or angiotensin receptor blocker restart
Resume the previous or an appropriately reduced dose only after reviewing the continuing indication, blood pressure, volume state, creatinine and potassium; follow disease-specific and local titration guidance.Avoid automatic restart during ongoing hypovolaemia, severe hypotension or uncontrolled hyperkalaemia. Arrange post-restart creatinine and potassium testing, and explain any expected small haemodynamic creatinine change in context.
Loop diuretic review
Individualise the oral or intravenous dose to congestion, symptoms, blood pressure and prior response; do not use a fixed ‘renal recovery’ dose or prescribe solely to force urine output.Over-diuresis can produce hypovolaemia, hypotension and recurrent AKI, while under-treatment leaves harmful congestion. Monitor weight, symptoms, renal function and electrolytes, and provide a clear adjustment plan where appropriate.
06Targets, monitoring and follow-upResponse, safety and longer-term review.
- Schedule serum creatinine and electrolytes according to discharge stability and residual impairment, with earlier testing for severe AKI, incomplete recovery, heart failure, transplant or a medicine restart.
- At every result review, compare with baseline, peak and discharge values and document the intended action; an unowned abnormal result is a failed follow-up pathway.
- Assess urine ACR after acute confounders settle and incorporate persistent albuminuria into CKD staging, cardiovascular risk reduction and referral decisions.
- Monitor blood pressure, postural symptoms, weight, oedema and breathlessness so biochemical surveillance does not miss recurrent depletion or congestion.
- After restarting ACE inhibitor, ARB, mineralocorticoid antagonist, diuretic or another renal-sensitive medicine, use the current disease-specific laboratory interval and respond to potassium and creatinine change.
- Maintain an AKI history flag and review recurrent episodes, non-prescribed NSAID use and sick-day understanding during future long-term-condition reviews.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
A falling creatinine can mislead
Loss of muscle during critical illness reduces creatinine generation, so a value apparently back at baseline may overstate filtration recovery. Functional status and later stable measurements help resolve this.
Ninety days defines chronicity
Persistent abnormal filtration or kidney-damage markers across at least three months supports CKD. Before that point, describe the residual abnormality and ensure it is not lost to follow-up.
Albumin adds prognostic information
Creatinine alone cannot show all residual injury. Albuminuria identifies glomerular damage and independently informs kidney and cardiovascular risk even when eGFR has recovered.
Restarting is active prescribing
‘Held during AKI’ is not a permanent diagnosis. The prescriber should revisit the original indication, current contraindications and monitoring so beneficial therapy is neither abandoned nor restarted blindly.
Heart failure needs integration
Renal values can worsen from both venous congestion and reduced perfusion. Interpreting creatinine without weight, blood pressure, symptoms and diuretic response risks treating the wrong haemodynamic problem.
08Common pitfallsFrequent interpretation and management errors.
- 01
Writing ‘AKI resolved’ without baseline, peak, stage or residual value prevents the next clinician from judging recovery and recurrent injury accurately.
- 02
Requesting repeat renal bloods without assigning who will see and act on the result creates a safety gap even when the interval itself is appropriate.
- 03
Leaving ACE inhibitor, ARB or diuretic therapy stopped indefinitely after a temporary hold can worsen heart failure, hypertension and albuminuric kidney disease.
- 04
Giving generic sick-day advice without naming medicines, triggers, maximum interruption and restart conditions can cause dehydration-related harm or prolonged undertreatment.
- 05
Assuming normal creatinine excludes ongoing kidney damage misses persistent albuminuria and underestimates future renal and cardiovascular risk.